During the past 40 years, cytokines and cytokine receptors have been extensively
investigated as either cancer targets or cancer treatments. A strong preclinical rationale …

CD8+ T cells are end effectors of cancer immunity. Most forms of effective cancer
immunotherapy involve CD8+ T cell effector function. Here, we review the current …

Chimeric antigen receptor (CAR) T cell therapy has garnered significant excitement due to
its success for hematological malignancies in clinical studies leading to the US Food and …

The field of chimeric antigen receptor (CAR) modified T cell therapy has rapidly expanded in
the past few decades. As of today, there are six CAR T cell products that have been …

Emerging reports show that metabolic pathways can be targeted to enhance T cell-mediated
immunity to tumors. Yet, tumors consume key metabolites in the host to survive, thus robbing …

Tumor immunotherapy, particularly the use of immune checkpoint inhibitors, has yielded
impressive clinical benefits. Therefore, it is critical to accurately screen individuals for …

The success of cancer immunotherapy in solid tumors depends on a sufficient distribution of
effector T cells into malignant lesions. However, immune-cold tumors utilize many T-cell …

Original research: Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and
TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas - PMC Back …

Spearheaded by the therapeutic use of chimeric antigen receptors (CARs) targeting CD19,
synthetic immunology has entered the clinical arena. CARs are recombinant receptors for …

Cytokines are immunoregulatory proteins involved in many pathological states with
promising potential as therapeutic agents. A diverse array of cytokines has been studied in …